TP53 and triple-negative breast carcinoma: The benefits of employing a PI3K/mTOR inhibitor in TP53 mutants were shown in a recent study, where a decrease in the proliferation of TP53 mutant, triple negative breast cancer cells was achieved through mutp53 degradation by PI3K/mTOR inhibition [132].